Breaking News

0 350
Power Solutions International Inc PSIX Stock News

Power Solutions International Inc (NASDAQ: PSIX)

Power Solutions International is having an incredibly strong start to the trading session today. While we are still in the pre-market hours, the stock is up substantially, which has prompted our friends at Trade Ideas to send the alert. At the moment (8:33), PSIX is trading at $10:15 per share after a gain of 58.59% thus far today.





Why PSIX Is Gaining

Late last  night in after-hours, a press release was offered showing that Power Solutions International had signed a stock purchase agreement with Weichai America Corp. According to the agreement, Weichai America plans on investing $60 million into the company in exchange for both common equity and perferred shares.

On top of the stock purchase agreement, a strategic collaboration agreement was signed between PSIX and Weichai America. The companies intend to work together to speed up the pace at which they penetrate the market with regard to the respective product lines of the two. This collaboration will extend across various geographic markets and end user segments. For PSIX, this is great news, as this collaboration will give the company access to Weichai America’s international manufacturing facilities as well as their supply chain network. In a statement, Gary Winemaster, Chairman and CEO at PSIX, had the following to offer:




The opportunity to partner with a global leader like Weichai enables PSI to strengthen our capital structure and significantly accelerate our growth trajectory. Through this alliance, we will dramatically expand adoption of our engines and technologies for transportation, power generation, and industrial applications within our current markets, including China, the world’s largest market opportunity. In addition, through access to Weichai’s extensive and complementary product offering, we will greatly expand our range of products, increasing the size of our overall addressable market across all of our end user segments. The combination of broader and deeper product set, enhanced financial strength and expanded geographic reach will enable PSI to better serve a larger customer base and deliver long-term shareholder value. Lastly, it positions us nicely to exceed our original long-term sales target of $1 billion.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on PSIX. In particular, we’ll be following the relationship between this company and Weichai to see the benefit associated with the stock purchase and collaboration agreements. Of course, these agreements are huge, as they bring quite a bit of strength through the doors for both sides of the equation. We’ll continue to follow the story and bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 577
Cancer Genetics, Inc. CGIX Stock News

Cancer Genetics, Inc. (CGIX) shareholders must certainly be pleased with the stock performance during the prior three trading days. On Monday, shares of CGIX closed higher by over 29%, ending the regular trading session at $5.05 a share. Since the beginning of 2017, shares are now higher by over 260%. With a market cap now approaching $100 million, investor interest has spiked after the company announced record fourth quarter and full year financials for 2016.

A rising share price is a good indicator of investor sentiment, however, even without that conviction, CGIX is taking care of business on its own.  And while the sudden interest is a bonus, the company is deserving of the praise.





Is CGIX Worthy?

CGIX wore the face of bravado last week, reporting an extremely robust fourth quarter and full year set of 2016 financials, complimented by positive guidance for 2017. With a market cap of roughly $96 million after Monday’s close, current share prices may, in actuality, be somewhat cheap.

CGIX, a leader in enabling precision medicine for oncology through molecular markers and diagnostics, reported impressive growth among a host of financial categories. For 2016, company revenues increased by over 50% to $27 million, up from $18 million in 2015. Fourth quarter revenue piled on a 32% increase year-over-year, banking additional income through organic growth to the tune of $7.2 million. Full-year 2016 gross profit also increased significantly, with margins being posted at 37%, up from 22% during the prior year. Altogether, the results lead to a net loss decrease of over 51%, and the company believes that the pathway to profitability is now paved.




Cash liquidity is also sound, with CGIX closing on a $12 million debt financing on March 22, 2017. Additionally, CGIX indicated that they are now working with nine of the ten largest pharma and biotech companies and that based on the company’s strategic decision to focus on solid tumors and hereditary cancers, CGIX has gained considerable traction, leverage, and market share in the immuno-oncology sector. As of the fourth quarter of 2016, CGIX has increased the number of clinical studies that it is currently supporting by over 50% and is now active in 125 current trials.

The company’s clinical services revenue saw a nice spike as well, increasing by over 88% to $10.7 million for the year. The momentum continued through the fourth quarter, improving by 25% over the same period in 2015. Again, the growth was organic in nature, with clinical test volumes increasing by 131% over the prior year with 28,658 current clinical trials.

CGIX is hitting on all cylinders, with each business category at the company recording substantial increases in a year-over-year comparison. The company is taking advantage of its recent acquisitions, with the integration and synergistic values beginning to perform as intended. These accretive benefits have increased the operating leverage across the company, leading to substantial, targeted, and specific gains in market share.

Commenting on the strong quarter, Panna Sharma, President and CEO, stated,“As we integrated our US sites, we achieved record margins during Q4 which we expect will continue rising as we grow revenue and capabilities. We have also started a major initiative to make our information and molecular data more valuable to both our biopharma customers and healthcare systems. We expect that this big-data and artificial intelligence initiative will further expand our margins while increasing our value to the oncology ecosystem.”

Will CGIX Keep The Momentum?

CGIX has no intention of letting up on the accelerator in 2017. According to Mr. Sharma, “During 2017 we expect our business to continue high double-digit, durable growth while continuing to innovate in the development and delivery of precision diagnostics and testing for oncology. We believe that we have a clear path towards achieving profitability, and accelerating our market share through partnerships and collaborations in areas that are becoming increasingly critical to the next generation of breakthroughs in patient care…”

Mr. Sharma added, “Technologies and trends such as artificial intelligence, big-data, and combining genomic and immune-marker testing to improve patient outcomes and accelerate the discovery of new therapeutics are all areas that CGI will be integrating into our business model and our global business infrastructure. Our growing reach into the oncology ecosystem coupled with the strengthening of our operating fundamentals makes CGI a leader in developing and delivering oncology diagnostics from bench to bedside.”

Perhaps investors should take this company to heart. CGIX ended the quarter with approximately $42 million in current assets, and roughly $23 million of those assets sit in cash and cash equivalents. Looking to the company’s consolidated statement of operations, CGIX showed remarkable year-over-year improvement, substantially reducing the bottom line loss to 1.00 per share, a 96% improvement over year end 2015.

CGIX is expanding with discipline and is in the process of developing a global footprint with locations in the US, India, and China. The company has established strong clinical research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC, and the National Cancer Institute.

The company’s service offerings include a comprehensive range of laboratory services that provide critical genomic and biomarker information, and also boasts that their state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

Volume Precedes Price

The presence and resurgence of trading volume is a welcome sight, as the shares have been able to hold recent gains through a combination of increased liquidity and spurred investor interest. Shares of CGIX have historically traded at higher levels, and at current prices, CGIX may be trending back toward its 2013 IPO price of $10.00 per share. The volume surge and investor interest may also be driven by the fact that the stock is now trading above the $5.00 level, which opens the door to additional institutional investment consideration.

While chasing a stock is not typically a wise move for any investor, nibbling at these levels may be justified based on the current financial position of the company, buoyed by the revenue momentum recorded through the end of the year. Dollar cost averaging may be the best bet here, and no stock goes straight up, regardless of the promises made. For 2017, CGIX may very well prove to be a winner, despite what may turn out to be a turbulent market based on the political and fragile economic climate.

The adage “volume precedes price” is certainly apropos in CGIX’s case, with volume, price, and current technical data indicating the potential for continued near-term momentum. What investors need to keep in mind, though, is that despite the likelihood of manipulative head-fakes and midday share dumps, CGIX, for the mid- to longer-term, has certainly established themselves as a potential major player in the immuno-oncology space. Thus, pullbacks may be beneficial for a cost-averaging investor looking to build a position in the company.

For now, the stars are well-aligned at CGIX, and if the company produces on their optimistic guidance for 2017, then shares purchased at current levels may turn out to be quite a bargain.

Disclosure: This article was written by Kenny Soulstring, and it reflects my own opinions and unique articulation. This article is not intended to offer investing advice, guarantee 100% accurate predictions, or to be interpreted as providing a personal recommendation. What I can guarantee, though, is accurate research, thoughtful analysis, and an enthusiasm about any stock that I cover.

While I seek to uncover emerging companies that I feel have true value and potential, it’s important that investors assign an appropriate time horizon to each of their investments, understanding that emerging companies need time to mature.

I wrote this article myself and it includes my own research and expresses my own opinions. I am not receiving compensation for it (other than from CNA Finance). I have no business relationship with any company whose stock is mentioned in this article.

Additional Disclosure: I have no position in any stock mentioned, but may initiate a long position in CGIX within the next 72 hours.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 446
TESARO Inc TSRO Stock News

TESARO Inc (NASDAQ: TSRO)

TESARO wasn’t having the best of days in the market today. In fact, the stock was halted at 3:23, trading in the red, which prompted our friends at Trade Ideas to send an alert about it. As we researched, we found overwhelmingly positive news that suggests that this stock is going to fly.





FDA Approves TSRO Niraparib

As mentioned above, TESARO wasn’t having the best of times in the market today. In fact, throughout the entire day, the stock has been trading in the red. However, at 3:23, the stock was halted with news pending, trading at $156.73 per share after a loss of $3.27 per share or 2.04%. We have found the pending news.




It looks like the halt is the result of the United States Food and Drug Administration making the decision to approve ZEJULA (niraparib) for the maintenance treatment of adults whoe are dealing with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. For more details with regard to the approval, click here!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on TSRO. In particular, we’re interested in learning about the company’s next steps following this news of FDA approval. Considering the overwhelming need for a treatment like this, we could see a massive gain in the stock as investors will expect for the treatment to be overwhelmingly profitable.

What Do You Think?

Where do you think TSRO is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

Kate Spade & Co KATE Stock News

Kate Spade & Co (NYSE: KATE)

Kate Spade is having an incredibly strong day in the market today, and for good reason. Reports are breaking that the company may announce that it has been acquired relatively soon. As a result, investors are flocking to the stock, leading to gains and prompting our partners at Trade Ideas to alert us to the movement. At the moment (11:01), KATE is trading at $23.58 per share after a gain of $0.39 per share (1.66%) thus far today.





KATE Gains On Acquisition Hopes

As mentioned above, Kate Spade is having an overwhelmingly strong start to the day today, and for good reason. Stories are breaking that Bank of America is saying that Coach (COH) will likely be acquiring KATE in a deal that will be announced relatively soon. Of course, neither KATE or COH are commenting on the story at the moment, but given the source of the story, we expect that this is very valid.




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on KATE. In particular, we’re interested in following the acquisition story as news may break relatively soon that COH is buying the company. We’ll continue to follow the story closely and bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

Check Out What The Trading Community Is Saying On StockTwits!

0 417
Impax Laboratories Inc IPXL Stock News

Impax Laboratories Inc (NASDAQ: IPXL)

Impax Laboratories is having an overwhelmingly strong day in the market today, and for good reason. Investors are cheering the appointment of a new CEO. As a result, the stock is flying high, which prompted our partners at Trade Ideas to alert us of the gains. At the moment (10:16), IPXL is trading at $11:18 per share after a gain of $1.93 per share or 20.81% thus far today.





IPXL Appoints Paul M. Bisaro As President And CEO

As mentioned above, Impax Laboratories is having an incredibly strong day in the market today after announcing the appointment of a new CEO. In a press release, the company announced that Paul M. Bisaro has been appointed as the President and CEO of the company.

Bisaro brings 25 years of generic and branded pharmaceutical experience to IPXL. He has a strong, successful record as a global business leader. Bisaro has served as executive chairman at Allergan as well as President and CEO of Actavis. In a statement, Robert L. Burr, Chairman at IPXL had the following to offer…




We are pleased to have Paul, a highly respected and accomplished leader, with a strong track record of delivering superior shareholder returns and financial performance, join Impax as our new CEO… Following a thorough review of candidates, the Board determined that Paul’s broad experience across the specialty pharmaceutical industry and demonstrated ability to grow and transform an organization, make him the right person to oversee the Company’s future direction. On behalf of the entire Board, I would also like to thank Keven for his leadership in stepping into the interim CEO role.”

The above statement was followed up by incoming CEO, Mr. Bisaro, with the following…

I am excited about the opportunity to lead Impax to its full potential in a rapidly changing environment… Impax has a strong reputation for its drug delivery, formulation and product development capabilities. We will continue to focus on developing high-quality products that meet the unique needs of our patients. Combining our R&D priorities with providing best in class customer service will provide additional value to our customers and deliver value for our shareholders.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance Team will be keeping a close eye on IPXL. In particular, we’re interested in watching the evolution of the company as Mr. Bisaro takes control. Nonetheless, we’ll continue to follow the story closely and bring you the news as it breaks!

What Do You Think?

Where do you think IPXL is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Check Out What The Trading Community Is Saying On StockTwits!

[Image Courtesy of Pixabay]

0 359
Sonoma Pharmaceuticals Inc SNOA Stock News

Sonoma Pharmaceuticals Inc (NASDAQ: SNOA)

Sonoma Pharmaceuticals was off to a relatively normal start to the trading session today. However, minutes ago, that all changed as a 510(k) clearance from the FDA hit center stage, causing the stock to spike dramatically and prompting our partners at Trade Ideas to alert us of the movement. At the moment (10:21), SNOA is trading at $7.24 per share after a gain of $0.15 per share or 2.12% thus far today, but is likely to fly far higher.





Why SNOA Is Climbing

As mentioned above, minutes ago, the FDA awarded Sonoma Pharmaceuticals a 510(k) clearance. The clearance was given for the company’s skin descaling product known as Loyon. As of yet, we have not received any comment from the company itself. However, you can see on the FDA website that SNOA has indeed been granted the 510(k).




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on SNOA. In particular, we’re interested in learning about the company’s next steps following the 510(k) approval news. Nonetheless, we’ll continue to follow the story incredibly closely and bring you the news as it breaks!

What Do You Think?

Where do you think SNOA is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 410
ZIOPHARM Oncology Inc. ZIOP Stock News

ZIOPHARM Oncology Inc. (NASDAQ: ZIOP)

ZIOPHARM Oncology is having a pretty interesting start to the trading session today. At the open, the stock was already trading green before falling to the red. However, it quickly spiked back to the green. The company announced positive guidance from the FDA early this morning, causing the movement and prompting our partners at Trade Ideas to send an alert. At the moment (9:46), ZIOP is trading at $5.93 per share after a gain of $0.05 per share (0.85%) thus far today.





ZIOP Receives Positive Guidance From The FDA

As mentioned above, the movement that we’re seeing from ZIOPHARM Oncology is likely the result of guidance the company received from the United States Food and Drug Administration (FDA). The company announced that it has received positive guidance from an End-of-Phase 2 meeting with the FDA surrounding its lead candidate, Ad-RTS-hIL-12 plus orally administered veledimex as a treatment for recurrent glioblastoma. In a statement, Laurence Cooper, M.D., Ph.D., CEO at ZIOP, had the following to offer:




We are pleased with our productive interactions with the FDA and the value direction we received at the End-of-Phase 2 meeting. Our controlled approach utilizing the RheoSwitch platform represents the next-generation of gene therapy enabling IL-12 to be regulated through a transcriptional switch. We appreciate the FDA’s feedback surrounding our plans to advance Ad-RTS-hIL-12 based therapy to a pivotal registration study for patients with recurrent GBM in 2017 and look forward to establishing the benefits of this novel therapeutic approach…”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ZIOP. In particular, we’re interesting in following the company through the development of Ad-RTS-hiL-12-based therapy and excited to see the progress ahead. We’ll continue to follow the stock closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikipedia]

Check Out What The Trading Community Is Saying On StockTwits!

0 892
HTG Molecular Diagnostics Inc HTGM Stock News

HTG Molecular Diagnostics Inc (NASDAQ: HTGM)

HTG Molecular Diagnostics is having an overwhelmingly strong start to today’s trading session, following up on the massive gains the stock saw to close the week off last week. As a result of the skyward movement, our partners at Trade Ideas sent the alert that brought the stock to our attention. At the moment (9:30), HTGM is trading at $11.89 per share after a gain fo $2.24 per share (23.21%) thus far today.





Why HTGM Is Gaining

As mentioned above, HTG Molecular Diagnostics is having an incredibly strong start to today’s trading session; but why is the stock gaining so big? As soon as we received the alert, the CNA Finance team started digging in to answer that question. It didn’t take long to dig up the story.




Ultimately, the gains are the result of a pre-market announcement in which HTGM informed investors that it had successfully adapted HTG EdgeSeq with the QIAGEN GeneReader NGS System. This is great news, as many shorts said this couldn’t happen. As a result of the news, investor excitement ensued, leading to big gains.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on HTGM. In particular, we’ll be watching for more news surrounding HTG EdgeSeq, as this has been a primary reason for recent gains on the stock. We’ll continue to follow the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

Check Out What The Trading Community Is Saying On StockTwits!

0 326
Paratek Pharmaceuticals Inc PRTK Stock News

Paratek Pharmaceuticals Inc (NASDAQ: PRTK) | Allergan Rg (NYSE: AGN)

Paratek Pharmaceuticals is having an incredibly strong start in the pre-market hours today, and for good reason. The company is gaining as the result of excitement surrounding a study the company is working on in collaboration with Allergan. In a press release issued this morning, the companies announced positive results from two trials they are working on in collaboration. Shortly after the release, the stock started to spike, prompting our partners at Trade Ideas to alert us of the move. Currently (9:05), PRTK is trading at $18.24 per share after a gain of $2.40 per share or 15.11% thus far today.





PRTK And AGN Announce Positive Clinical Results

As mentioned above Paratek Pharmaceuticals is having an overwhelmingly strong time in the market after reporting positive clinical data from 2 Phase 3 clinical trials it has been working on in collaboration with Allergan. The trials both revolve around sarecycline as a treatment for moderate to severe acne. In the press release, the companies informed investors that both trials had met their 12 week primary endpoints.

In a statement, Evan Loh, M.D., President, CEO and CMO at PRTK had the following to offer…




We are pleased with the results of the sarecycline Phase 3 program and Allergan’s intention to move ahead with an NDA submission for approval in the U.S. by the end of 2017… Sarecycline is a narrow spectrum antibiotic, which we believe can offer meaningful clinical benefits for patients afflicted with acne.”

What We’ll Be Watching For Ahead

Looking ahead, the CNA Finance team will be keeping a close eye on both PRTK and AGN. In particular, we’re interested in following the process as the companies push sarecycline toward FDA approval. Nonetheless, we’ll continue to follow the story closely and bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Check Out What The Trading Community Is Saying On StockTwits!

[Image courtesy of Pixabay]

0 672
Cellect Biotechnology Ltd APOP Stock News

Cellect Biotechnology Ltd (NASDAQ: APOP)

Cellect Biotechnology is having an incredibly strong start to the trading session in the pre-market hours, and for good reason. Early this morning, the company announced its first stem cell transplant. As a result, excitement led to a frenzy among investors, pushing the stock up in a big way and prompting our partners at Trade Ideas to send us the alert. At the moment (8:53), APOP is trading at $7.74 per share after a gain of $1.45 per share (23.05%) thus far today.





APOP Announces First Patient Stem Cell Transplant

As mentioned above, Cellect Biotechnology is having a strong start to the day in the market after announcing its first stem cell transplant. According to the PR released by the company today, the first stem cell transplant procedure has been successfully completed using the company’s proprietary ApoGraft(TM) technology. This transplant is the first in the company’s Phase I/II clinical trial in the treatment of blood cancer. In a statement, Dr. Shai Yarkoni, CEO at APOP, had the following to offer:




After 15 years of research, this is the first time we have used our technology on a cancer patient suffering from life-threatening conditions. It is a first good step on a road that we hope will lead to stem cell based regenerative medicine becoming a safe commodity treatment at every hospital in the world.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping an incredibly close eye on APOP. In particular, we’re interested in following the company’s work with regard to ApoGraft, as this could be a game changer in the oncology space. We’ll continue to follow the story and bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

Check Out What The Trading Community Is Saying On StockTwits!

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 3890
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...